Inovio Pharmaceuticals, Inc. (INO)

NASDAQ: INO · IEX Real-Time Price · USD

10.13

-0.04 (-0.34%)

At close: Apr 25, 2024, 4:00 PM

10.24

+0.12 (1.14%)

After-hours: Apr 25, 2024, 7:11 PM EDT

Inovio Pharmaceuticals Balance Sheet

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Year	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013 - 1998
Cash & Equivalents	14.31	46.33	71.14	250.73	22.2	23.69	23.79	19.14	57.63	40.54	Upgrade
Short-Term Investments	130.98	206.67	330.17	160.91	67.34	57.54	103.64	85.63	105.36	53.08	Upgrade
Cash & Cash Equivalents	145.29	253	401.31	411.64	89.53	81.23	127.43	104.77	162.99	93.62	Upgrade
Cash Growth	-42.57%	-36.96%	-2.51%	359.76%	10.22%	-36.25%	21.63%	-35.72%	74.10%	77.56%	Upgrade
Receivables	2.41	11.74	8.03	19.06	2.03	4.05	6.49	16.57	7.33	2.8	Upgrade
Other Current Assets	5.41	50.51	39.1	40.46	2.63	2.53	4.45	3.26	1.53	2.52	Upgrade
Total Current Assets	153.11	315.24	448.44	471.17	94.2	87.81	138.36	124.6	171.85	98.95	Upgrade
Property, Plant & Equipment	14.45	17.96	29.02	24.09	26.56	15.95	18.32	9.03	7.31	4.58	Upgrade
Long-Term Investments	2.78	2.01	3.91	4.89	6.32	9.41	11.39	19.83	19.99	12.34	Upgrade
Goodwill and Intangibles	0	12.64	13.14	13.66	14.21	15.27	16.52	18.14	14.02	14.89	Upgrade
Other Long-Term Assets	0.61	0.68	1.43	25.96	2.67	2.67	2.64	2.11	0.68	1.02	Upgrade
Total Long-Term Assets	17.84	33.29	47.5	68.6	49.75	43.3	48.88	49.11	41.99	32.84	Upgrade
Total Assets	170.95	348.53	495.94	539.77	143.95	131.11	187.24	173.71	213.84	131.79	Upgrade
Accounts Payable	20.92	80.91	48.19	21.85	18.97	24.11	24.21	20.67	13.23	6.41	Upgrade
Deferred Revenue	0	0	0.09	0.13	0.23	0.41	1.57	15.57	14.73	4.59	Upgrade
Current Debt	19.18	2.8	2.6	2.33	2.07	0	0	0	0	0	Upgrade
Other Current Liabilities	2.47	13.16	14.86	17.4	10.72	10.78	9.63	7.58	3.5	3.08	Upgrade
Total Current Liabilities	42.57	96.87	65.74	41.71	31.99	35.3	35.41	43.82	31.47	14.09	Upgrade
Long-Term Debt	11.03	29.27	30.42	36.72	97.43	0	0	0	0	0	Upgrade
Other Long-Term Liabilities	0	0.03	0.11	0.21	9.12	8.78	9.35	6.51	6.44	6.16	Upgrade
Total Long-Term Liabilities	11.03	29.3	30.53	36.93	106.56	8.78	9.35	6.51	6.44	6.16	Upgrade
Total Liabilities	53.6	126.17	96.27	78.63	138.55	44.08	44.75	50.33	37.91	20.25	Upgrade
Total Debt	30.21	32.07	33.02	39.05	99.51	0	0	0	0	0	Upgrade
Debt Growth	-5.82%	-2.87%	-15.43%	-60.76%	-	-	-	-	-	-	Upgrade
Retained Earnings	-1,622.97	-1,487.85	-1,209.86	-906.2	-739.79	-620.43	-523.36	-434.84	-361.1	-331.91	Upgrade
Comprehensive Income	-0.66	-0.7	-0.28	-0.26	0.47	-0.53	-0.12	1.33	2.71	-0.25	Upgrade
Shareholders' Equity	117.35	222.36	399.67	461.14	3.44	86.94	142.39	123.28	175.69	111.23	Upgrade
Net Cash / Debt	115.08	220.92	368.29	372.59	-9.97	81.23	127.43	104.77	162.99	93.62	Upgrade
Net Cash / Debt Growth	-47.91%	-40.01%	-1.15%	-	-	-36.25%	21.63%	-35.72%	74.10%	77.56%	Upgrade
Net Cash Per Share	5.19	11.11	21.16	28.82	-1.21	10.53	18.67	17.17	28.61	18.91	Upgrade
Working Capital	110.54	218.37	382.7	429.46	62.21	52.52	102.96	80.77	140.38	84.86	Upgrade
Book Value Per Share	5.29	11.18	22.97	35.67	0.42	11.27	20.89	20.21	30.91	22.57	Upgrade

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).